MX2014010272A - Derivados del acido fenil alcanoico como agonistas gpr. - Google Patents
Derivados del acido fenil alcanoico como agonistas gpr.Info
- Publication number
- MX2014010272A MX2014010272A MX2014010272A MX2014010272A MX2014010272A MX 2014010272 A MX2014010272 A MX 2014010272A MX 2014010272 A MX2014010272 A MX 2014010272A MX 2014010272 A MX2014010272 A MX 2014010272A MX 2014010272 A MX2014010272 A MX 2014010272A
- Authority
- MX
- Mexico
- Prior art keywords
- alkyl
- phenyl
- methoxy
- halo
- amino
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/06—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/06—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
- C07D307/08—Preparation of tetrahydrofuran
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epoxy Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261603988P | 2012-02-28 | 2012-02-28 | |
| US201261736622P | 2012-12-13 | 2012-12-13 | |
| PCT/IB2013/051555 WO2013128378A1 (en) | 2012-02-28 | 2013-02-27 | Phenyl alkanoic acid derivatives as gpr agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2014010272A true MX2014010272A (es) | 2015-08-14 |
Family
ID=48225087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014010272A MX2014010272A (es) | 2012-02-28 | 2013-02-27 | Derivados del acido fenil alcanoico como agonistas gpr. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20150072969A1 (enExample) |
| EP (1) | EP2820005A1 (enExample) |
| JP (1) | JP2015508809A (enExample) |
| KR (1) | KR20140138243A (enExample) |
| CN (1) | CN104144920A (enExample) |
| AR (1) | AR090191A1 (enExample) |
| AU (1) | AU2013227266A1 (enExample) |
| CA (1) | CA2866210A1 (enExample) |
| IL (1) | IL234254A (enExample) |
| IN (1) | IN2014MN01839A (enExample) |
| MX (1) | MX2014010272A (enExample) |
| NZ (1) | NZ631569A (enExample) |
| RU (1) | RU2014138894A (enExample) |
| TW (1) | TW201341356A (enExample) |
| WO (1) | WO2013128378A1 (enExample) |
| ZA (1) | ZA201407034B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140097127A (ko) | 2011-09-16 | 2014-08-06 | 포비어 파마수티칼스 | 아닐린 유도체, 그의 제조법 및 그의 치료 용도 |
| WO2015028960A1 (en) * | 2013-08-28 | 2015-03-05 | Piramal Enterprises Limited | Substituted heterocyclic derivatives as gpr agonists and uses thereof |
| US10011609B2 (en) | 2013-11-14 | 2018-07-03 | Cadila Healthcare Limited | Heterocyclic compounds |
| US9957219B2 (en) | 2013-12-04 | 2018-05-01 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| EP3102198B1 (en) | 2014-02-06 | 2020-08-26 | Merck Sharp & Dohme Corp. | Antidiabetic compounds |
| AU2015220427B2 (en) | 2014-02-19 | 2017-09-21 | Piramal Enterprises Limited | Compounds for use as GPR120 agonists |
| EP3172185B1 (en) * | 2014-07-25 | 2020-03-04 | Piramal Enterprises Limited | Substituted phenyl alkanoic acid compounds as gpr120 agonists and uses thereof |
| WO2016022742A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| EP3177282B1 (en) | 2014-08-08 | 2021-10-06 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| EP3177285B1 (en) | 2014-08-08 | 2020-09-23 | Merck Sharp & Dohme Corp. | [5,6]-fused bicyclic antidiabetic compounds |
| WO2016019587A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [7, 6]-fused bicyclic antidiabetic compounds |
| WO2016032120A1 (ko) * | 2014-08-27 | 2016-03-03 | 씨제이헬스케어 주식회사 | 신규한 아미노-페닐-설포닐-아세테이트 유도체 및 이의 용도 |
| KR101641023B1 (ko) | 2014-08-27 | 2016-07-20 | 씨제이헬스케어 주식회사 | 신규한 아미노-페닐-설포닐-아세테이트 유도체 및 이의 용도 |
| CA2960757C (en) | 2014-09-11 | 2022-09-06 | Piramal Enterprises Limited | Fused heterocyclic compounds as gpr120 agonists |
| WO2019134984A1 (en) | 2018-01-08 | 2019-07-11 | Celon Pharma S.A. | 3-phenyl-4-hexynoic acid derivatives as gpr40 agonists |
| UA126458C2 (uk) | 2018-02-13 | 2022-10-05 | Гіліад Сайєнсіз, Інк. | Інгібітори pd-1/pd-l1 |
| US10899735B2 (en) | 2018-04-19 | 2021-01-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| EP3820572B1 (en) | 2018-07-13 | 2023-08-16 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| AU2019366355B2 (en) | 2018-10-24 | 2022-10-13 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| WO2021071837A1 (en) | 2019-10-07 | 2021-04-15 | Kallyope, Inc. | Gpr119 agonists |
| TW202140440A (zh) | 2020-02-28 | 2021-11-01 | 美商克力歐普股份有限公司 | Gpr40激動劑 |
| UY39222A (es) | 2020-05-19 | 2021-11-30 | Kallyope Inc | Activadores de la ampk |
| AU2021297323A1 (en) | 2020-06-26 | 2023-02-16 | Kallyope, Inc. | AMPK activators |
| WO2024211164A2 (en) * | 2023-04-03 | 2024-10-10 | Trustees Of Dartmouth College | Fatty acid mimetics as modulators of gpr40 and/or gpr120 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK281577B6 (sk) * | 1994-10-18 | 2001-05-10 | Pfizer Inc. | Heterocyklické zlúčeniny a farmaceutický prostriedok na ich báze |
| JP3400392B2 (ja) * | 1994-10-18 | 2003-04-28 | ファイザー製薬株式会社 | ５−リポキシゲナーゼ阻害剤及び新規医薬組成物 |
| US5883106A (en) * | 1994-10-18 | 1999-03-16 | Pfizer Inc. | 5-lipoxygenase inhibitors |
| US6403632B1 (en) * | 2000-03-01 | 2002-06-11 | Bristol Myers Squibb Pharma Co | Lactam metalloprotease inhibitors |
| EP1250332A1 (en) * | 1999-12-17 | 2002-10-23 | Abbott Laboratories | Inhibitors of interleukin 5 gene expression |
| GB0214149D0 (en) | 2002-06-19 | 2002-07-31 | Glaxo Group Ltd | Chemical compounds |
| AU2003261319A1 (en) * | 2002-08-01 | 2004-02-23 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme |
| WO2005054213A1 (ja) * | 2003-12-02 | 2005-06-16 | Shionogi & Co., Ltd. | ペルオキシソーム増殖活性化受容体アゴニスト活性を有するイソキサゾール誘導体 |
| AU2005220728B2 (en) | 2004-02-27 | 2009-08-06 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders |
| WO2005117909A2 (en) | 2004-04-23 | 2005-12-15 | Exelixis, Inc. | Kinase modulators and methods of use |
| BRPI0618319A2 (pt) * | 2005-11-07 | 2011-08-23 | Irm Llc | compostos e composições como moduladores de ppar |
| US7935689B2 (en) * | 2006-05-18 | 2011-05-03 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| RS53230B (sr) * | 2006-06-27 | 2014-08-29 | Takeda Pharmaceutical Company Limited | Kondenzovana ciklična jedinjenja kao modulatori gpr40 receptora |
| TW200838526A (en) * | 2006-12-01 | 2008-10-01 | Astellas Pharma Inc | Carboxylic acid derivatives |
| EP2205548A1 (en) * | 2007-10-10 | 2010-07-14 | Amgen, Inc | Substituted biphenyl gpr40 modulators |
| US8217064B2 (en) * | 2007-12-20 | 2012-07-10 | Envivo Pharmaceuticals, Inc. | Tetrasubstituted benzenes |
| US8450522B2 (en) | 2008-03-06 | 2013-05-28 | Amgen Inc. | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders |
| JP5551707B2 (ja) | 2008-10-15 | 2014-07-16 | アムジエン・インコーポレーテツド | スピロ環ｇｐｒ４０調節因子 |
| AU2009307656B2 (en) * | 2008-10-21 | 2015-07-02 | Cymabay Therapeutics, Inc. | Aryl GPR120 receptor agonists and uses thereof |
| MX2011005025A (es) * | 2008-11-14 | 2011-05-30 | Bayer Schering Pharma Ag | Compuestos de arilo con sustituyentes heterociclicos como inhibidores hif. |
| JPWO2010123016A1 (ja) | 2009-04-22 | 2012-10-25 | アステラス製薬株式会社 | カルボン酸化合物 |
| WO2010138901A1 (en) * | 2009-05-29 | 2010-12-02 | Biogen Idec Ma Inc | Carboxylic acid-containing compounds, derivatives thereof, and related methods of use |
| AU2010272233A1 (en) * | 2009-07-17 | 2012-02-09 | Shire Llc | Novel carbamate amino acid and peptide prodrugs of opioids and uses thereof |
| DE102009046115A1 (de) * | 2009-10-28 | 2011-09-08 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 3-Phenylpropansäuren und ihre Verwendung |
| CA2805808A1 (en) | 2010-07-23 | 2012-01-26 | Connexios Life Sciences Pvt. Ltd. | Agonists of gpr40 |
| WO2012082817A1 (en) * | 2010-12-16 | 2012-06-21 | Boehringer Ingelheim International Gmbh | Biarylamide inhibitors of leukotriene production |
-
2013
- 2013-02-27 AU AU2013227266A patent/AU2013227266A1/en not_active Abandoned
- 2013-02-27 EP EP13719305.8A patent/EP2820005A1/en not_active Withdrawn
- 2013-02-27 US US14/381,696 patent/US20150072969A1/en not_active Abandoned
- 2013-02-27 KR KR1020147027497A patent/KR20140138243A/ko not_active Withdrawn
- 2013-02-27 MX MX2014010272A patent/MX2014010272A/es unknown
- 2013-02-27 CN CN201380011377.0A patent/CN104144920A/zh active Pending
- 2013-02-27 RU RU2014138894A patent/RU2014138894A/ru not_active Application Discontinuation
- 2013-02-27 TW TW102106971A patent/TW201341356A/zh unknown
- 2013-02-27 NZ NZ631569A patent/NZ631569A/en not_active IP Right Cessation
- 2013-02-27 IN IN1839MUN2014 patent/IN2014MN01839A/en unknown
- 2013-02-27 JP JP2014559335A patent/JP2015508809A/ja active Pending
- 2013-02-27 CA CA2866210A patent/CA2866210A1/en not_active Abandoned
- 2013-02-27 WO PCT/IB2013/051555 patent/WO2013128378A1/en not_active Ceased
- 2013-02-28 AR ARP130100630A patent/AR090191A1/es unknown
-
2014
- 2014-08-21 IL IL234254A patent/IL234254A/en not_active IP Right Cessation
- 2014-09-26 ZA ZA2014/07034A patent/ZA201407034B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2014138894A (ru) | 2016-04-20 |
| CN104144920A (zh) | 2014-11-12 |
| IN2014MN01839A (enExample) | 2015-07-03 |
| US20150072969A1 (en) | 2015-03-12 |
| KR20140138243A (ko) | 2014-12-03 |
| WO2013128378A1 (en) | 2013-09-06 |
| ZA201407034B (en) | 2017-08-30 |
| EP2820005A1 (en) | 2015-01-07 |
| TW201341356A (zh) | 2013-10-16 |
| NZ631569A (en) | 2016-10-28 |
| IL234254A (en) | 2017-03-30 |
| AR090191A1 (es) | 2014-10-29 |
| CA2866210A1 (en) | 2013-09-06 |
| JP2015508809A (ja) | 2015-03-23 |
| AU2013227266A1 (en) | 2014-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014010272A (es) | Derivados del acido fenil alcanoico como agonistas gpr. | |
| AU2021237185B2 (en) | GLP-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same | |
| EP3172185B1 (en) | Substituted phenyl alkanoic acid compounds as gpr120 agonists and uses thereof | |
| JP6095580B2 (ja) | 芳香環化合物 | |
| WO2013122029A1 (ja) | 芳香環化合物 | |
| WO2014170842A2 (en) | Substituted alkyl carboxylic acid derivatives as gpr agonists | |
| KR102563111B1 (ko) | Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법 | |
| EP3191463B1 (en) | Fused heterocyclic compounds as gpr120 agonists | |
| JP2017530986A (ja) | ２型糖尿病治療のためのｇｐｒ４０アゴニストとしての置換ベンゾチオフェニル誘導体 | |
| WO2015028960A1 (en) | Substituted heterocyclic derivatives as gpr agonists and uses thereof | |
| KR101942752B1 (ko) | Ｇｐｒ120 효능제로서의 티오아릴 유도체 | |
| US11773077B2 (en) | Compounds containing carbon-carbon linker as GPR120 agonists | |
| RU2800290C1 (ru) | Агонист рецептора glp-1, фармацевтическая композиция, содержащая его, и способ его приготовления | |
| NZ733800B2 (en) | Compounds containing carbon-carbon linker as gpr120 agonists | |
| JP2006527215A (ja) | パラ置換されたフェニルカルバメート |